May 8 (Reuters) - Neurocrine Biosciences Inc NBIX.O:
NEUROCRINE BIOSCIENCES ANNOUNCES NEW RESULTS FROM EXPLORATORY ANALYSES OF THE PHASE 3 CAHTALYST™ PEDIATRIC STUDY DEMONSTRATING CRENESSITY™ REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING OR IMPROVING ANDROSTENEDIONE ACROSS PATIENT SUBGROUPS
NEUROCRINE BIOSCIENCES INC - CRENESSITY REDUCES GLUCOCORTICOID DOSING WHILE MAINTAINING ANDROSTENEDIONE LEVELS
NEUROCRINE BIOSCIENCES INC - DATA CONSISTENT ACROSS ALL PATIENT SUBGROUPS IN CAHTALYST STUDY
NEUROCRINE BIOSCIENCES INC - CRENESSITY GENERALLY WELL TOLERATED IN CAHTALYST STUDY
Source text: ID:nPn8gq8hNa
Further company coverage: NBIX.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.